On Nov 20, major Wall Street analysts update their ratings for $Medtronic (MDT.US)$, with price targets ranging from $90 to $105.
Morgan Stanley analyst Patrick Wood maintains with a buy rating, and maintains the target price at $98.
BofA Securities analyst Travis Steed maintains with a buy rating, and sets the target price at $100.
Citi analyst Joanne Wuensch maintains with a hold rating, and maintains the target price at $92.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $105.
UBS analyst Danielle Antalffy maintains with a hold rating, and adjusts the target price from $90 to $93.
Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:
Although maintaining a positive outlook for the FY25 high single-digit EPS growth rate as an indicator for future performance, analysts note the company will face challenges into FY26 with ongoing FX pressures, dilutive effects from new products and capital rollouts, and slight tax headwinds, which may impede a steady return to high single-digit EPS growth.
Medtronic's Q2 revenue outperformed expectations largely due to strong performance in the cardiovascular, neuro, and diabetes sectors. Furthermore, the company has increased its FY25 growth projections to between 4.75%-5.0%. Analysts maintain a positive outlook into FY26, anticipating that earnings growth may surpass overall revenue growth.
Here are the latest investment ratings and price targets for $Medtronic (MDT.US)$ from 11 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月20日，多家華爾街大行更新了$美敦力 (MDT.US)$的評級，目標價介於90美元至105美元。
摩根士丹利分析師Patrick Wood維持買入評級，維持目標價98美元。
美銀證券分析師Travis Steed維持買入評級，目標價100美元。
花旗分析師Joanne Wuensch維持持有評級，維持目標價92美元。
巴克萊銀行分析師Matt Miksic維持買入評級，維持目標價105美元。
瑞士銀行分析師Danielle Antalffy維持持有評級，並將目標價從90美元上調至93美元。
此外，綜合報道，$美敦力 (MDT.US)$近期主要分析師觀點如下：
儘管對於FY25高單位數每股收益增長率保持樂觀展望，作爲未來表現的指標，但分析師指出，隨着外匯壓力、新產品和資本推出的稀釋效應，以及輕微的稅務阻力，公司在FY26將面臨挑戰，這可能會妨礙其穩定回歸高單位數每股收益增長。
美敦力第二季度營業收入超出預期，主要得益於心血管、神經和糖尿病領域的強勁表現。此外，該公司已將FY25增長預測上調至4.75%-5.0%之間。分析師對FY26持樂觀態度，預計盈利增長可能超過整體營業收入增長。
以下爲今日11位分析師對$美敦力 (MDT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
